DDAH I Antibodies

Santa Cruz Biotechnology delivers a wide array of DDAH I monoclonal antibodies for investigating dimethylarginine dimethylaminohydrolase I. DDAH I Antibodies are validated for multiple applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). DDAH I plays a central role in regulating nitric oxide synthesis by metabolizing asymmetric dimethylarginine (ADMA), a known inhibitor of nitric oxide synthase. This regulation is essential for maintaining cardiovascular health and has implications in various diseases, including hypertension and atherosclerosis. Research focused on DDAH I can provide insights into therapeutic targets for cardiovascular conditions. DDAH I monoclonal antibodies enable detailed examination of nitric oxide regulation pathways in cellular and molecular studies. Researchers can explore the relationship between DDAH I expression and various pathological conditions. Advanced visualization techniques using DDAH I monoclonal antibodies allow for precise localization and quantification studies. Santa Cruz Biotechnology monoclonal antibodies for DDAH I support researchers worldwide in advancing our understanding of cardiovascular disease mechanisms and potential treatments.